Artivion, Inc. (NYSE:AORT) SVP Sells $11,936.88 in Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 472 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.29, for a total transaction of $11,936.88. Following the sale, the senior vice president now directly owns 172,743 shares of the company’s stock, valued at $4,368,670.47. This represents a 0.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Artivion Stock Down 2.0 %

Shares of NYSE AORT opened at $24.22 on Friday. The company has a 50 day simple moving average of $29.13 and a 200 day simple moving average of $27.81. The firm has a market cap of $1.02 billion, a PE ratio of -1,211.00 and a beta of 1.79. Artivion, Inc. has a 1 year low of $19.11 and a 1 year high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. JMP Securities reissued a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC dropped their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Finally, Stifel Nicolaus dropped their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $31.40.

Institutional Trading of Artivion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in Artivion by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after purchasing an additional 46,267 shares during the period. Wasatch Advisors LP increased its position in Artivion by 27.7% during the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after purchasing an additional 226,160 shares during the period. Next Century Growth Investors LLC increased its position in Artivion by 29.7% during the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company’s stock valued at $14,085,000 after purchasing an additional 112,918 shares during the period. Northern Trust Corp increased its position in Artivion by 10.0% during the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company’s stock valued at $13,244,000 after purchasing an additional 42,170 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Artivion by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company’s stock valued at $10,241,000 after purchasing an additional 8,343 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.